MIM
FBIO icon

MetLife Investment Management’s Fortress Biotech FBIO Stock Holding History

MetLife Investment Management’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,038
Closed -$123K – 2285
2020
Q3 		$123K Buy
+2,038
New +$104K ﹤0.01% 2113

Other funds holding FBIO

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SAM
Shikiar Asset Management New York $347M AUM 23.44% 1-Year Est. Return

MetLife Investment Management's FBIO Position: Q4 2020 in Review

MetLife Investment Management sold out of Fortress Biotech (FBIO) in Q4 2020, closing a stake of 2,038 shares — an estimated $123K sold.

MetLife Investment Management first reported a position in FBIO in Q3 2020 and held it in 1 quarter. The position peaked at $123K in Q3 2020. 87 funds tracked by Wall St. Rank hold FBIO as of Q4 2020.

  • MetLife Investment Management reported no remaining Fortress Biotech position as of Q4 2020 after selling out during the quarter.
  • MetLife Investment Management sold 2,038 Fortress Biotech shares in Q4 2020, an estimated $123K.
  • MetLife Investment Management first reported a position in Fortress Biotech in Q3 2020 and held it in 1 quarter.
  • MetLife Investment Management's Fortress Biotech position peaked at $123K in Q3 2020.
  • 87 funds tracked by Wall St. Rank held Fortress Biotech as of Q4 2020.

Based on MetLife Investment Management's 13F filing for Q4 2020, filed 16 Feb 2021.